GNLX · Genelux Corporation — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on GNLX. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About GNLX · Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Live Quote
SELL (score -5) · 12-1 mom 5.0% · RSI 49.6 · above_50_only · -64.6% from high
Targets blend Wall Street consensus (6 analysts: low $10.00 / mean $17.50 / high $31.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
GNTX is a clinical-stage oncolytic viral immunotherapy company with a single product candidate (Olvi-Vec) in a Phase 3 ovarian cancer registrational trial expected to read out in H2:26. The pipeline trigger cited four Form 4 filings in the prior 14 days as an insider cluster, but every recent filing was coded 'S' — tax-withholding sales upon RSU vesting by four different insiders (CEO Zindrick $8.2K, CSO Yu ~$1.8K, CTO Cappello ~$1.8K, Head of Regulatory Smalling ~$0.8K). None were open-market P-purchases. The August-September 2025 cluster showed option-repricing (exercise price reduced from up to $22.40 to $3.33) — not equity purchases either. Zero genuine insider buying detected across all filings reviewed. With $26M cash, ~$9M quarterly burn, a pending $100M ATM facility, no revenue, and options markets too illiquid for practical structuring, there is no actionable mispricing or smart-money edge in this name at current levels.